pipeline-prospector-insert-v1
X

Find Oncology Drugs in Phase I Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EOS-850

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Minister of Economy and Research

            Deal Size: $16.4 million Upfront Cash: Undisclosed

            Deal Type: Funding January 30, 2020

            Details:

            Funds will be used to progress iTeos’ two highly innovative clinical-stage oncology programs: a best-in class A2A receptor antagonist and an ADCC-enabled anti-TIGIT antibody drug candidate

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GMI-1359

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020

            Details:

            Proof-of-concept Phase 1b trial evaluating safety and biomarkers of anti-cancer effect in patients with hormone receptor positive metastatic breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BI 1701963

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020

            Details:

            Boehringer Ingelheim initiates Phase 1 trial for a FORMA-discovered, BI-licensed protein-protein interaction program and BMS initiates Phase 1B trial for FORMA-discovered, Celgene-licensed pan BET inhibitor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aldoxorubicin

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: ImmunityBio

            Deal Size: $343.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement January 29, 2020

            Details:

            CytRx out-licensed global development, manufacturing, and commercialization rights for aldoxorubicin to ImmunityBio Inc. in July 2017.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACTR707,Trastuzumab

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            Cohort 1 recruitment is complete with no dose-limiting toxicity reported in the ATTCK-34-01 Phase 1 trial testing Unum's novel ACTR707 antibody-coupled T cell receptor investigational therapy with trastuzumab.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SY-5609,Fulvestrant

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            SY-5609 has shown substantial anti-tumor activity, including complete regressions, in multiple preclinical models of solid tumors, at doses below the maximum tolerated dose (MTD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IK-175

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            The launch of the first-in-human clinical study within three years of the beginning of the research program underscores the rapid progress IK-175 in Patients with Advanced Solid Tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TILT-123

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biotheus

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            Details:

            Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ficlatuzumab,Paclitaxel,Gemcitabine

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            The study, was designed to determine the maximum tolerated dose of ficlatuzumab when combined with gemcitabine and nab-paclitaxel.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORIC-101,Enzalutamide

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            Study based on preclinical evidence suggesting ORIC-101, may inhibit a potential mechanism of resistance to XTANDI® in patients with metastatic prostate cancer.

            PharmaCompass